… A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in
patients with gastroesophageal adenocarcinomas stratified according to primary tumor location …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

… -label phase II trial, patients with resected stage IA to IIIA (7 th edition of the American Joint
Committee on Cancer staging system) EGFR-mutant NSCLC were treated with erlotinib 150 …

… recommended phase II dose identified was cetuximab 500 mg/m 2 every 2 weeks and erlotinib
… This article reports the results of a trial combining erlotinib and cetuximab in patients with …

… To some extent, the conclusion of the present study was almost the same as that of the
earlier randomised phase II study, in which gefitinib and erlotinib showed similar efficacy and …

… efficacy of erlotinib, dosed to achieve a rash, in patients (pts) with PC. Methods: Erlotinib was
… The dose of erlotinib was increased by 50mg every 2 weeks (maximum 300 mg/day) until > …

… Results from our phase II trial do not support the hypothesis, based on preclinical synergy,
that the combination of erlotinib plus bevacizumab would be broadly useful in unselected, …

… Combinations of targeted therapies also warrant investigation in this setting: erlotinib plus
bevacizumab produced promising antitumor activity in a phase I/II trial involving patients with …

… NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial.
… was 3.38 months for sorafenib/erlotinib versus 1.77 months for placebo/erlotinib (P = .018); …

… This phase II evaluation of first-line treatment with erlotinib in minimally selected patients
yielded a satisfactory outcome with minimal toxicity. Despite a modest 15% response rate, the …